V

Vimian Group AB
STO:VIMIAN

Watchlist Manager
Vimian Group AB
STO:VIMIAN
Watchlist
Price: 28.86 SEK -1.16% Market Closed
Market Cap: 15.2B SEK

Vimian Group AB
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vimian Group AB
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
V
Vimian Group AB
STO:VIMIAN
Net Issuance of Debt
-€6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
OssDsign AB
STO:OSSD
Net Issuance of Debt
-kr1.3m
CAGR 3-Years
-22%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Xvivo Perfusion AB
STO:XVIVO
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
D
Doxa AB
STO:DOXA
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bactiguard Holding AB
STO:BACTI B
Net Issuance of Debt
-kr66.6m
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
S2Medical AB (publ)
STO:S2M
Net Issuance of Debt
-kr8.5m
CAGR 3-Years
-154%
CAGR 5-Years
-64%
CAGR 10-Years
N/A
No Stocks Found

Vimian Group AB
Glance View

Market Cap
15.2B SEK
Industry
Health Care

Vimian Group AB is a relatively new player making waves in the veterinary and animal health industries. Founded in Sweden, Vimian is structured as a conglomerate composed of specialized subsidiaries focused on different niche markets within veterinary services, diagnostics, and technology. This strategic structure enables the company to operate across various segments such as Veterinary Services, Specialty Pharma, MedTech, and Diagnostics, achieving a holistic approach to animal healthcare. By acquiring and partnering with innovative companies globally, Vimian capitalizes on synergies and cross-market opportunities, ensuring a competitive edge in each of its operational fields. The company’s diverse portfolio allows it to cater not only to pet owners and veterinary professionals but also to livestock industries, ensuring comprehensive coverage in the growing market of animal welfare and health. Vimian’s revenue streams are multi-faceted, generated from a blend of product sales, subscriptions, and service fees. For instance, within its Specialty Pharma segment, the company develops and sells pharmaceutical products designed to treat common and specialty conditions in animals, thus generating continuous revenue from veterinary practices worldwide. In the MedTech segment, Vimian offers cutting-edge medical devices and equipment, enhancing veterinary surgical and diagnostic capabilities, which drives sales. Meanwhile, their Diagnostics division provides innovative testing solutions that help veterinarians identify and treat animal diseases accurately, offering another lucrative revenue stream. This multi-pronged business model not only mitigates risk through diversification but also positions Vimian as a key player in meeting the rapidly evolving demands of animal health and care.

VIMIAN Intrinsic Value
40.84 SEK
Undervaluation 29%
Intrinsic Value
Price
V

See Also

What is Vimian Group AB's Net Issuance of Debt?
Net Issuance of Debt
-6m EUR

Based on the financial report for Sep 30, 2025, Vimian Group AB's Net Issuance of Debt amounts to -6m EUR.

What is Vimian Group AB's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
93%

Over the last year, the Net Issuance of Debt growth was 93%.

Back to Top